Pub Date : 2023-01-28DOI: 10.1007/s13665-023-00301-4
R. Jablonski
{"title":"Lung Cancer and Lung Transplantation","authors":"R. Jablonski","doi":"10.1007/s13665-023-00301-4","DOIUrl":"https://doi.org/10.1007/s13665-023-00301-4","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":"12 1","pages":"1-9"},"PeriodicalIF":0.6,"publicationDate":"2023-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45469429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-23DOI: 10.1007/s13665-023-00299-9
D. Sethi, V. Kouritas, E. Mishra
{"title":"Factors Affecting Rate of Pleural Fluid Accumulation in Patients with Malignant Pleural Effusions","authors":"D. Sethi, V. Kouritas, E. Mishra","doi":"10.1007/s13665-023-00299-9","DOIUrl":"https://doi.org/10.1007/s13665-023-00299-9","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":"12 1","pages":"10-15"},"PeriodicalIF":0.6,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47851884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1007/s13665-023-00302-3
Daniel Z P Friedman, Natasha N Pettit, Erica MacKenzie, Jennifer Pisano
Purpose of review: The landscape of the coronavirus disease 2019 (COVID-19) pandemic has rapidly changed over the past 3 years. Paralleling this evolution, the scientific and medical communities have reported many novel findings relating to the infection's epidemiology, transmission, diagnosis, and treatment. We review pertinent studies of COVID-19 therapeutics with an emphasis on their application to lung transplant recipients.
Recent findings: Agents that have been well-studied for treating COVID-19 include antivirals (remdesivir, nirmatrelvir/ritonavir, molnupiravir), monoclonal antibodies, and immunomodulators (for example, corticosteroids and tocilizumab).
Summary: Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.
{"title":"Current and Emerging Therapies for COVID-19 in Lung Transplantation.","authors":"Daniel Z P Friedman, Natasha N Pettit, Erica MacKenzie, Jennifer Pisano","doi":"10.1007/s13665-023-00302-3","DOIUrl":"https://doi.org/10.1007/s13665-023-00302-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>The landscape of the coronavirus disease 2019 (COVID-19) pandemic has rapidly changed over the past 3 years. Paralleling this evolution, the scientific and medical communities have reported many novel findings relating to the infection's epidemiology, transmission, diagnosis, and treatment. We review pertinent studies of COVID-19 therapeutics with an emphasis on their application to lung transplant recipients.</p><p><strong>Recent findings: </strong>Agents that have been well-studied for treating COVID-19 include antivirals (remdesivir, nirmatrelvir/ritonavir, molnupiravir), monoclonal antibodies, and immunomodulators (for example, corticosteroids and tocilizumab).</p><p><strong>Summary: </strong>Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.</p>","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":"12 2","pages":"23-35"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9493812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01Epub Date: 2023-04-11DOI: 10.1007/s13665-023-00307-y
Mark Robertshaw, Corey D Kershaw
Purpose of review: This review aims to summarize the available literature to identify the incidence and risk factors for persistent interstitial lung abnormalities (ILAs) following hospitalization for COVID-19. The current and prospective treatment options are reviewed in an effort to help pulmonary practitioners care for this burgeoning patient population.
Recent findings: Statistical modeling suggests that 11.7% of all patients hospitalized with COVID-19 have irreversible fibrotic features on long-term follow-up imaging.
Summary: The available evidence suggests that up to 30% of patients have ILAs following COVID-19 hospitalization. The radiographic abnormalities improve or resolve in a majority of these patients. However, estimates suggest that up to one-third of these patients have irreversible fibrotic features. Clinical trials of the impact of anti-fibrotic agents are ongoing. As there continue to be thousands of COVID-19 hospitalizations in the USA each week, the management of post-COVID ILAs will become a common problem for the pulmonary practitioner.
{"title":"Post COVID Interstitial Lung Abnormalities-Incidence and Management.","authors":"Mark Robertshaw, Corey D Kershaw","doi":"10.1007/s13665-023-00307-y","DOIUrl":"10.1007/s13665-023-00307-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to summarize the available literature to identify the incidence and risk factors for persistent interstitial lung abnormalities (ILAs) following hospitalization for COVID-19. The current and prospective treatment options are reviewed in an effort to help pulmonary practitioners care for this burgeoning patient population.</p><p><strong>Recent findings: </strong>Statistical modeling suggests that 11.7% of all patients hospitalized with COVID-19 have irreversible fibrotic features on long-term follow-up imaging.</p><p><strong>Summary: </strong>The available evidence suggests that up to 30% of patients have ILAs following COVID-19 hospitalization. The radiographic abnormalities improve or resolve in a majority of these patients. However, estimates suggest that up to one-third of these patients have irreversible fibrotic features. Clinical trials of the impact of anti-fibrotic agents are ongoing. As there continue to be thousands of COVID-19 hospitalizations in the USA each week, the management of post-COVID ILAs will become a common problem for the pulmonary practitioner.</p>","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":"12 2","pages":"64-69"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9551072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-29DOI: 10.1007/s13665-022-00298-2
E. Fraser, P. Weeratunga, L. Ho
{"title":"Management of Sarcoidosis: When to Treat, How to Treat and for How Long?","authors":"E. Fraser, P. Weeratunga, L. Ho","doi":"10.1007/s13665-022-00298-2","DOIUrl":"https://doi.org/10.1007/s13665-022-00298-2","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":"11 1","pages":"151 - 159"},"PeriodicalIF":0.6,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46514934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-15DOI: 10.1007/s13665-022-00297-3
K. Wojnowski, M. Mayo, Jose Carlos Garcia Blanco, A. Abreu, A. Chediak
{"title":"Comorbid Narcolepsy and Obstructive Sleep Apnea: A Review","authors":"K. Wojnowski, M. Mayo, Jose Carlos Garcia Blanco, A. Abreu, A. Chediak","doi":"10.1007/s13665-022-00297-3","DOIUrl":"https://doi.org/10.1007/s13665-022-00297-3","url":null,"abstract":"","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":"11 1","pages":"160-165"},"PeriodicalIF":0.6,"publicationDate":"2022-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42420917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号